About: Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients()

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients() Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients()
Creator	Brossas, J.-Y Brun, S Datry, A Fekkar, A Gauthier, L Gay, F Imbert, S Joly, I Mazier, D Touafek, F Uzunov, M
Source	PMC
abstract	We evaluated the usefulness of a serum Aspergillus PCR assay for the diagnosis and prognosis of invasive aspergillosis in a study involving 941 patients for a total of 5146 serum samples. Fifty-one patients had proven/probable aspergillosis. We compared galactomannan (GM), PCR and mycologic analysis of pulmonary samples in both neutropenic and nonneutropenic patients. PCR performed in serum yielded 66.7% sensitivity, 98.7% specificity, 75.6% positive predictive value and 98.0% negative predictive value, while the GM index yielded 78.4% sensitivity, 87.5% specificity, 27% positive predictive value and 98.6% negative predictive value. The inclusion of PCR in the European Organization for Research and Treatment of Cancer (EORTC) and the Mycosis Study Group (MSG) mycologic criteria permitted the reclassification of nine other cases from possible to probable aspergillosis and increased the sensitivity to 71.7%. Combining the GM index with serum PCR increased the detection rate of invasive aspergillosis with 88.2% sensitivity. PCR was systematically negative in 16 patients with noninvasive forms of aspergillosis (namely aspergilloma and chronic aspergillosis). Remaining PCR positive after a period of 14 to 20 days of treatment was related to poor outcome at 30 and 90 days. Our results also indicate that, unlike the determination of the GM index, the initial fungus load as determined by PCR was highly predictive of 90-day mortality, with the rate of the latter being 15.8% for patients with <150 copies/mL vs. 73.2% for patients at or above that cutoff (p <0.0001). Therefore, PCR appears to be a powerful and interesting tool for the identification of patients with invasive aspergillosis who might benefit from more intense care.
has issue date	2016-02-17(xsd:dateTime)
bibo:doi	10.1016/j.cmi.2016.01.027
bibo:pmid	26899830
has license	no-cc
sha1sum (hex)	ff966b5218e3c9433966d622a806710b820a60d6
schema:url	https://doi.org/10.1016/j.cmi.2016.01.027
resource representing a document's title	Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients()
has PubMed Central identifier	PMC7129605
has PubMed identifier	26899830
schema:publication	Clin Microbiol Infect
resource representing a document's body	covid:ff966b5218e3c9433966d622a806710b820a60d6#body_text
is schema:about of	named entity 'determination' named entity 'sensitivity' named entity 'patients' named entity 'serum' named entity 'sensitivity' named entity 'samples' named entity 'PCR' named entity 'assay' named entity 'powerful' named entity 'PCR' named entity 'diagnosis' named entity 'neutropenic' named entity 'INVASIVE ASPERGILLOSIS' named entity 'SENSITIVITY' named entity '28P' named entity 'SERUM' named entity 'PERFORMED' named entity 'DAY' named entity 'COPIES' named entity '87.5' named entity 'COMPARED' named entity 'INTERESTING' named entity 'REMAINING' named entity 'INDEX' named entity 'POOR OUTCOME' named entity 'NONINVASIVE' named entity 'PROVEN' named entity 'HIGHLY' named entity 'STUDY GROUP' named entity 'PROGNOSIS' named entity 'FORMS' named entity 'POSITIVE PREDICTIVE VALUE' covid:arg/ff966b5218e3c9433966d622a806710b820a60d6 named entity 'TOTAL' named entity 'FOLLOW-UP' named entity 'INVASIVE ASPERGILLOSIS' named entity 'PATIENTS' named entity 'STUDY' named entity 'MYCOSIS' named entity 'CARE' named entity 'INVOLVING' named entity 'DETERMINATION' named entity 'DIAGNOSIS' named entity 'SERUM' named entity 'PROGNOSIS' named entity 'LOAD' named entity 'MORTALITY' named entity 'ASPERGILLOMA' named entity 'ASPERGILLUS' named entity 'ANALYSIS' named entity 'PCR' named entity 'CRITERIA' named entity 'PCR' named entity 'PCR POSITIVE' named entity 'CASES' named entity 'PROBABLE' named entity 'TREATMENT' named entity 'TOOL' named entity 'EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER' named entity 'PREDICTIVE' named entity 'NEGATIVE' named entity 'ASPERGILLOSIS' named entity 'SPECIFICITY' named entity 'ASPERGILLUS' named entity 'RATE' named entity 'PERMITTED' named entity 'POSSIBLE' named entity 'RELATED' named entity 'IDENTIFICATION' named entity 'BENEFIT' named entity 'FIFTY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software